Related Experiment Video

Updated: Oct 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Drug Therapy of Lipid Disorders: Benefits and Limitations in Elderly Patients

Leonard S. Lilly1

  • 1Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.

The American Journal of Geriatric Cardiology
|October 1, 1996
PubMed

Insights

Lipid-lowering drug therapy reduces cardiovascular risks but its use in elderly patients with hyperlipidemia remains controversial due to limited clinical trial data. Benefits must be weighed against potential risks in this population.

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Pharmacologic therapy for lipid disorders is established for reducing cardiovascular morbidity and mortality.
  • Treatment of hyperlipidemia in the elderly population is controversial.
  • Scant clinical trial data exists for anti-lipid drug use in older individuals.

Purpose of the Study:

  • To evaluate the established role of pharmacologic therapy in managing lipid disorders.
  • To address the controversy surrounding lipid-lowering drug use in the elderly.
  • To highlight the need for careful consideration of benefits versus risks in older patients.

Main Methods:

  • Review of existing clinical trial data concerning lipid disorders in the elderly.
  • Analysis of current recommendations for anti-lipid drug use in older individuals.
  • Weighing potential benefits of pharmacologic therapy against inherent treatment risks.

Main Results:

  • Pharmacologic therapy is a proven method for reducing cardiovascular risks in the general population.
  • Limited evidence exists from large clinical trials specifically for the elderly with hyperlipidemia.
  • Current recommendations necessitate a risk-benefit analysis for anti-lipid drug use in older adults.

Conclusions:

  • The application of lipid-lowering therapies in the elderly requires careful consideration.
  • Limited data necessitates a cautious approach to prescribing anti-lipid drugs for older individuals.
  • Balancing potential cardiovascular benefits against age-related treatment risks is crucial for this demographic.

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...